Asset Details
Do you wish to reserve the book?
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
Do you wish to request the book?
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype
2011
Overview
Background and AimThe study of CD44/CD24 and ALDH1 expression is the most accurate method to identify cancer stem cells (CSC) from breast cancer populations. However, the overlap between CD44+CD24−/low and ALDH1high CSC phenotypes in breast cancer seems to be very small, as well as their distribution among intrinsic breast cancer subtypes. Due to this discrepancy, it is imperative to improve the understanding of breast CSC marker distribution.Methods466 invasive breast carcinomas and eight breast cancer cell lines were analysed for the expression of CD44, CD24 and ALDH1, to evaluate their distribution among the distinct molecular subtypes.ResultsBasal-like tumours (76.5%) contained the higher percentage of cells with the CSC phenotype CD44+CD24−/low (p<0.0001). From ALDH1-positive cases, 39.4% were also basal-like tumours (p<0.0001). The analysis of breast cancer cell lines indicated that luminal cell lines are mainly enriched in a CD44−/lowCD24+ cell population, basal/mesenchymal breast cancer cell lines are enriched in the CD44+CD24−/low phenotype, whereas the remaining basal/epithelial cell lines are mainly positive for both markers. ALDH1 activity was mainly found in HER-OE and basal/epithelial breast cancer cell.ConclusionsCD44+CD24−/low and ALDH1+ phenotypes seem to identify CSC with distinct levels of differentiation. It seems that the paramount method and biomarkers that identify breast CSC within the distinct molecular subtypes need to be better explored, because it is pivotal to translate the CSC concept to clinical practice. In the future, the recognition of reliable markers to distinguish the CSC pool in each molecular subtype will be decisive for the development of specific target therapies.
Publisher
BMJ Publishing Group Ltd and Association of Clinical Pathologists,BMJ Publishing Group,BMJ Publishing Group LTD
Subject
/ Aged
/ ALDH1
/ Biological and medical sciences
/ Biomarkers, Tumor - metabolism
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - mortality
/ Breast Neoplasms - pathology
/ CD24
/ CD44
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Hyaluronan Receptors - metabolism
/ Investigative techniques, diagnostic techniques (general aspects)
/ Neoplastic Stem Cells - metabolism
/ Neoplastic Stem Cells - pathology
/ Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
/ Retinal Dehydrogenase - metabolism
/ Tumors
